Clinical Trials Logo

Clinical Trial Summary

Hereditary hemorrhagic telangiectasia (HHT) is linked to a dysregulation of angiogenesis leading to the formation of arteriovenous malformations (AVM): cutaneo-mucous telangiectasia and visceral shunts. The diagnosis is clinical and based on Curaçao criteria: recurrent epistaxis, cutaneo-mucous telangiectasia, hereditary signs and presence of visceral AVM. Pulmonary AVMs (PAVM) expose patients to many potentially life-threatening complications, such as strokes or brain abscesses due to the right-left shunt created and the lack of filtration barrier of the pulmonary capillary within the AVM. These patients should therefore have regular monitoring throughout their life by a chest CT scanner every 5 to 10 years in the absence of PAVM at the initial scan or more often if PAVMs are present. The management of PAVMs is based on their early detection and embolization in interventional radiology during which is set up within the afferent artery of the PAVM an embolizing agent, the coil. However, the risk of cumulative irradiation exposure from thoracic scanners and repeated thoracic embolizations over time could be reduces by a decrease of X-rays dose. A new thoracic CT imaging protocol validated in the United States in the primary screening of lung cancer, the ultra-low dose protocol, is a CT scanner acquired at an irradiation dose equivalent to that of a frontal chest x-ray and in profile. The dose reduction is of 40 times the usual dose of a chest CT scanner. The lung parenchyma has a high natural contrast on thoracic CT images and there are few adjacent attenuating structures allowing a drastic reduction of dose. However, from this dose, the image quality is degraded with an increase of the image noise. The diagnostic performances have to be confirmed with qualitative and quantitative measurements. Thus, the objective of this study is to compare the sensitivity and the specificity of the current scanner and the ultra-low dose scanner to reduce the exposure to X-rays.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04108052
Study type Interventional
Source Hospices Civils de Lyon
Contact
Status Completed
Phase N/A
Start date November 28, 2019
Completion date May 28, 2021

See also
  Status Clinical Trial Phase
Completed NCT03227263 - BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). Phase 3
Completed NCT00733655 - Study of Histological Samples From Patients With Hereditary Haemorrhagic Telangiectasia
Completed NCT00355108 - ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome Phase 3
Completed NCT01507480 - The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia Phase 1
Completed NCT03910244 - Pomalidomide for the Treatment of Bleeding in HHT Phase 2
Recruiting NCT04976036 - Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients Phase 2
Completed NCT00684879 - Screening Behavior in Adults With Hereditary Hemorrhagic Telangiectasia
Completed NCT00004648 - Studies of Hereditary Hemorrhagic Telangiectasia N/A
Completed NCT00230672 - Investigation of Plasma Proteins in Patients With Hereditary Haemorrhagic Telangiectasia and PAVMs
Completed NCT03954782 - Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease. Phase 2
Completed NCT02484716 - Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO) Phase 2
Recruiting NCT00230685 - Case Notes Review on Patients With Hereditary Haemorrhagic Telangiectasia
Terminated NCT02204371 - Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia Phase 2
Recruiting NCT00230620 - Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families
Recruiting NCT02157987 - Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose Phase 1/Phase 2
Completed NCT01408030 - North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Phase 2
Completed NCT00230659 - Investigation of Coagulation Parameters in Hereditary Haemorrhagic Telangiectasia
Withdrawn NCT00733629 - Study of Endothelial Cells in Patients With Hereditary Haemorrhagic Telangiectasia
Active, not recruiting NCT00230633 - Studies of White Blood Cells Derived From HHT Patients
Recruiting NCT05933330 - Hereditary Hemorrhagic Telangiectasia and Neurovascular Manifestations, in the Danish HHT Database